Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysis
Authors:
- Juan HeJHJuan He
- Gong-Hao HeGHGong-Hao He
- Jian-Chang HeJHJian-Chang He
- Fan XuFXFan Xu
- Gui-Li XuGXGui-Li Xu
Open Access
- 23 October 2014
- journal article
- research article
- Published by Asian Pacific Organization for Cancer Prevention in Asian Pacific Journal of Cancer Prevention
- Vol. 15 (19) , 8331-8335
Abstract
Association of CYP2C19 Polymorphisms with Survival of Breast Cancer Patients Using Tamoxifen: Results of a Meta-analysis Breast cancer;$CYP2C19^*2$;$CYP2C19^*17$;survival;tamoxifen;meta-analysis; Background: Previous studies accessing the association of CYP2C19 with outcomes of patients using tamoxifen for breast cancer have yielded conflicting results. The aim of this meta-analysis is to obtain a more precise estimate of effects of CYP2C19 polymorphisms and to clarify their effects on survival of the breast cancer patients using tamoxifen. Materials and Methods: A systematic search of PubMed and Embase was performed, comparing patients with or without $CYP2C19^*2$ and $CYP2C19^*17$, relevant articles searched for. The following outcomes were included from the eligible studies: disease-free survival (DFS) and overall survival (OS), expressed by hazard ratios (HR) with corresponding 95% confidence interval (CI). Subgroup analysis by genotypes was also performed. Pooled estimates were calculated using random-effect model in accordance to the heterogeneity. Results: Six studies met the inclusion criteria. The integrated OR on the association between CYP2C19 and DFS, calculated by the random-effect model, was 0.54 (95%CI=0.34-0.84, p=0.013). Subgroup analysis showed that both $CYP2C19^*2$ and $CYP2C19^*17$ were associated with increased survival. The pooled results of two studies for OS were OR=0.46 (95%CI=0.21-1.01, p=0.233). Conclusions: This meta-analysis suggests that the $CYP2C19^*2$ and $CYP2C19^*17$ genotypes are associated with increased survival in breast cancer patients using tamoxifen.
Keywords
This publication has 32 references indexed in Scilit:
- CYP2C19*2 predicts substantial tamoxifen benefit in postmenopausal breast cancer patients randomized between adjuvant tamoxifen and no systemic treatmentBreast Cancer Research and Treatment, 2013
- Influence of CYP2D6 Polymorphisms on Serum Levels of Tamoxifen Metabolites in Spanish Women with Breast CancerInternational Journal of Medical Sciences, 2013
- SULT1A1 , CYP2C19 and Disease-Free Survival in early Breast Cancer Patients Receiving TamoxifenPharmacogenomics, 2011
- The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agentsBreast Cancer Research and Treatment, 2011
- Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analysesEuropean Journal of Epidemiology, 2010
- Associations between tamoxifen, estrogens, and FSH serum levels during steady state tamoxifen treatment of postmenopausal women with breast cancerBMC Cancer, 2010
- Efficacy of tamoxifen based on cytochrome P450 2D6, CYP2C19 and SULT1A1 genotype in the Italian Tamoxifen Prevention TrialThe Pharmacogenomics Journal, 2010
- Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17British Journal of Clinical Pharmacology, 2010
- CYP2C19*17 is associated with decreased breast cancer riskBreast Cancer Research and Treatment, 2008
- Measuring inconsistency in meta-analysesBMJ, 2003